# LEPROSY: SCIENCE & TECHNOLOGY

**NEWS:** India to employ targeted containment to stop transmission of leprosy

## WHAT'S IN THE NEWS?

Leprosy, also known as **Hansen's disease**, is a **chronic infectious disease** caused by *Mycobacterium leprae*. Despite being curable, it remains a significant public health concern due to **stigma**, **delayed diagnosis**, **and disability risks**. India, the country with the highest number of leprosy cases, has launched **various government initiatives** to eliminate the disease, with a target of achieving **zero transmission by 2027**.

# 1. Understanding Leprosy

#### A. Cause & Transmission

- Caused by: Mycobacterium leprae, a slow-growing bacterium affecting the skin and peripheral nerves.
- Mode of Transmission:
  - Spreads via prolonged, close contact with an untreated leprosy patient.
  - Primarily transmitted through respiratory droplets (coughing/sneezing).
  - Children are more susceptible than adults.
- Incubation Period:
  - Typically 3 to 5 years but can extend up to 20 years.

## **B. Symptoms & Effects**

- Early Symptoms:
  - Pale or reddish patches on the skin with loss of sensation.
  - Tingling, numbness, or muscle weakness in hands/feet.
- Advanced Symptoms (if untreated):
  - Severe skin lesions and disfigurement.
  - Permanent nerve damage, leading to disability.
  - Loss of sensation in affected areas, increasing injury risk.

## 2. Leprosy Treatment & New Drug Regimen



# PL RAJ IAS & IPS ACADEMY

#### MAKING YOU SERVE THE NATION

# A. Standard Treatment: Multi-Drug Therapy (MDT)

- WHO-recommended MDT consists of:
  - 1. Dapsone
  - 2. Rifampicin
  - 3. Clofazimine
- Duration of Treatment:
  - Paucibacillary Leprosy (PB) (Mild Cases): 6 months.
  - Multibacillary Leprosy (MB) (Severe Cases): 12 months.
- MDT is available free of cost under national programs.

# B. New Treatment Regimen (Effective April 2025)

- Change in Treatment Approach:
  - WHO revised MDT for Paucibacillary cases from a two-drug regimen to a three-drug regimen.
  - The Indian government has approved the revised regimen to accelerate elimination.
  - WHO will begin supplying the updated drugs from April 1, 2025.

# 3. Government Initiatives for Leprosy Eradication





# A. National Leprosy Eradication Programme (NLEP) (1983, under NHM)

- Objective:
  - Detect leprosy early and provide free treatment.
  - Prevent the occurrence of **Grade II Disability (G2D)**.
- Key Achievements:
  - 2005: India achieved "Elimination of Leprosy" as per WHO's criteria (less than 1 case per 10,000 population).
  - However, leprosy persists in some districts across states.
  - New case detection has declined:
    - **2014-15:** 1.25 lakh cases.
    - **2021-22:** 75,394 cases.
- High Burden States (5 States with the Most Cases):
- 1. Bihar
- 2. Chhattisgarh
- 3. **Jharkhand**
- 4. Maharashtra
- 5. Odisha
- B. National Strategic Plan (NSP) & Roadmap for Leprosy (2023-27)
  - Launched by: Ministry of Health in January 2023 under NLEP.
  - Goal: Achieve zero transmission of leprosy by 2027 (three years ahead of SDG 2030 target).
  - Key Focus Areas:
    - 1. Awareness & Stigma Reduction
      - Campaigns to eliminate social discrimination against patients.
    - 2. Early Detection & Screening
      - Door-to-door surveys for active case detection.
    - 3. Prophylaxis (Leprosy Post-Exposure Prophylaxis LPEP)



- **Preventive treatment** for high-risk individuals.
- 4. Digital Tracking (Nikusth 2.0 Portal)
  - A web-based system for real-time reporting and analysis of leprosy cases.

# 4. Leprosy as a Global Health Challenge

- Leprosy is still a Neglected Tropical Disease (NTD).
- It remains endemic in 120+ countries, with around 200,000 new cases annually.
- India accounts for nearly 60% of global leprosy cases.

**Source:** <a href="https://www.thehindu.com/sci-tech/health/govt-to-employ-targeted-containment-to-stop-transmission-of-leprosy/article69158608.ece">https://www.thehindu.com/sci-tech/health/govt-to-employ-targeted-containment-to-stop-transmission-of-leprosy/article69158608.ece</a>

